Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.
about
Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations.Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.Editorial: Bench to Bedside-and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe.Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study.
P2860
Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Correlations between changes i ...... g data from an imatinib study.
@ast
Correlations between changes i ...... g data from an imatinib study.
@en
type
label
Correlations between changes i ...... g data from an imatinib study.
@ast
Correlations between changes i ...... g data from an imatinib study.
@en
prefLabel
Correlations between changes i ...... g data from an imatinib study.
@ast
Correlations between changes i ...... g data from an imatinib study.
@en
P2093
P2860
P356
P1433
P1476
Correlations between changes i ...... ng data from an imatinib study
@en
P2093
Faye de Leon
Kelly L Summers
Kyle M Walker
Louise Vanderhoek
Shannon Seney
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEU216
P50
P577
2014-05-20T00:00:00Z